Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FAST alone Clear all

Conditions: Acute Lymphoblastic Leukemia
Interventions: Gross Motor Function, Knee extension strength, Hand grip strength, Flexibility, Ankle range of motion, Aerobic capacity, Body composition and vital signs; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 10 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Portland, Oregon • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more

Conditions: Hepatic Impairment
Interventions: Avacopan; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Formulation Bridging, Food Effect
Interventions: PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Healthy Volunteers
Interventions: AMG 378, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Lake Forest, California • Overland Park, Kansas

Conditions: Posttraumatic Stress Disorder
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Metolazone Tablets 5 mg, Zaroloxyn® Tablets 5 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Breast Cancer, Early-stage Breast Cancer
Interventions: Fasting; Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Infections, Respiratory Tract
Interventions: GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Effect of Food, Pharmacokinetics
Interventions: esomeprazole/ASA Fixed Dose Combination (FDC); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Oveland Park, Kansas

Conditions: Overweight and Obesity
Interventions: Full LIITA3H App, Partial LIITA3H App, LIITA3H Location only; Other
Lead sponsor: University of Michigan; Other
Eligibility: 13 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Fasting
Interventions: Desloratadine; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Healthy Volunteers
Interventions: A4250; Drug
Lead sponsor: Albireo; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Colonic Neoplasms
Interventions: Normal (0.9%) saline, HalfLytely; Drug
Lead sponsor: Arya, Vijaypal, M.D., P.C.; Individual
Eligibility: 21 Years to 70 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Middle Village, New York

Conditions: Overweight and Obesity, Eating Behavior
Interventions: Placebo, Bromocriptine-QR; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Opioid Dependence, Opioid Use Disorder (OUD)
Interventions: VK4-116, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Doxycycline Monohydrate; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Dose Finding Study
Interventions: TAK-828, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Austin, Texas

Conditions: Healthy
Interventions: Ondansetron Orally Disintegrating Tablets 8 mg, Zofran ODT® Tablets 8 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Fed
Interventions: CIPRO®XR; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Large B Cell Lymphoma
Interventions: 18F-FluorApoTrace; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
Interventions: Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 40 Years to 69 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Psoriasis, Psoriatic Arthritis
Interventions: Intermittent Fasting Diet; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Neoplasms
Interventions: Regorafenib (BAY73-4506) + rifampin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Prostate Cancer
Interventions: Enzalutamide Liquid, Enzalutamide Capsule; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Aerobic and Strengthening Exercise for Acute Leukemia

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants

Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy

Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg

Improving Nutritional Choices in Adolescents

Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.

Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions

Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

VK4-116 Phase I Study With Food-Effect

Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions

Imaging Apoptosis for Lymphoma Treatment Response

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer